We provide you with 20 years of free, institutional-grade data for RVMD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RVMD. Explore the full financial landscape of RVMD stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$43,397,797
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Patel Sushil | Sale | -5,580 | $183.17 | $1,022,107 | 2026-07-01 |
| Patel Sushil | Derivatives Exercise | 2,955 | 2026-07-01 | ||
| Anders Jack | Sale | -20,000 | $167.34 | $3,346,900 | 2026-06-26 |
| Anders Jack | Derivatives Exercise | 20,000 | 2026-06-26 | ||
| Kim Lorence H. | Grant, award...etc | 1,191 | 2026-06-23 | ||
| Borisy Alexis | Grant, award...etc | 1,191 | 2026-06-23 | ||
| ANDERSON ELIZABETH M | Grant, award...etc | 1,191 | 2026-06-23 | ||
| Horning Sandra | Grant, award...etc | 1,191 | 2026-06-23 | ||
| Clyburn Frank | Grant, award...etc | 1,191 | 2026-06-23 | ||
| Patel Sushil | Grant, award...etc | 1,191 | 2026-06-23 | ||
| Borellini Flavia | Grant, award...etc | 1,191 | 2026-06-23 | ||
| GOLDSMITH MARK A | Sale | -10,020 | $156.12 | $1,564,310 | 2026-06-18 |
| Cislini Jeff | Sale | -2,157 | $156.12 | $336,749 | 2026-06-18 |
| Anders Jack | Sale | -2,722 | $156.12 | $424,956 | 2026-06-18 |
| Kelsey Stephen Michael | Sale | -4,175 | $156.12 | $651,798 | 2026-06-18 |
| Mancini Anthony | Sale | -4,615 | $156.12 | $720,490 | 2026-06-18 |
| Horn Margaret A | Sale | -93,575 | $160.17 | $14,987,964 | 2026-06-17 |
| Horn Margaret A | Derivatives Exercise | 90,000 | 2026-06-17 | ||
| Horn Margaret A | Sale | -10,000 | $144.28 | $1,442,793 | 2026-06-15 |
| Horn Margaret A | Derivatives Exercise | 10,000 | 2026-06-15 | ||
| Mancini Anthony | Sale | -3,121 | $153.3 | $478,456 | 2026-05-28 |
| Mancini Anthony | Derivatives Exercise | 3,121 | 2026-05-28 | ||
| Mancini Anthony | Sale | -3,120 | $131.66 | $410,785 | 2026-04-29 |
| Mancini Anthony | Derivatives Exercise | 3,120 | 2026-04-29 | ||
| GOLDSMITH MARK A | Sale | -120,000 | $150.09 | $18,010,488 | 2026-04-17 |
| GOLDSMITH MARK A | Derivatives Exercise | 120,000 | 2026-04-17 | ||
| Mancini Anthony | Sale | -37,450 | $93.22 | $3,491,201 | 2026-03-26 |
| Mancini Anthony | Derivatives Exercise | 37,450 | 2026-03-26 | ||
| Mancini Anthony | Initial | 2026-03-26 | |||
| Sandler Alan B. | Initial | 2026-03-26 | |||
| Wei Lin | Sale | -2,073 | $99.48 | $206,223 | 2026-03-19 |
| Kelsey Stephen Michael | Sale | -4,302 | $99.48 | $427,965 | 2026-03-19 |
| GOLDSMITH MARK A | Sale | -12,871 | $99.48 | $1,280,412 | 2026-03-19 |
| Horn Margaret A | Sale | -4,583 | $99.48 | $455,919 | 2026-03-19 |
| Anders Jack | Sale | -2,753 | $99.48 | $273,870 | 2026-03-19 |
| Cislini Jeff | Sale | -2,958 | $99.48 | $294,263 | 2026-03-19 |
| Wang Xiaolin | Sale | -2,010 | $99.48 | $199,956 | 2026-03-19 |
| GOLDSMITH MARK A | Sale | -15,394 | $76.82 | $1,182,526 | 2025-12-18 |
| Kelsey Stephen Michael | Sale | -5,447 | $76.82 | $418,423 | 2025-12-18 |
| Horn Margaret A | Sale | -4,847 | $76.82 | $372,333 | 2025-12-18 |
| Anders Jack | Sale | -3,104 | $77.09 | $239,289 | 2025-12-18 |
| Cislini Jeff | Sale | -2,688 | $76.82 | $206,484 | 2025-12-18 |
| GOLDSMITH MARK A | Sale | -6,000 | $75 | $450,000 | 2025-11-26 |
| GOLDSMITH MARK A | Sale | -60,000 | $75.08 | $4,504,962 | 2025-11-26 |
| GOLDSMITH MARK A | Derivatives Exercise | 60,000 | 2025-11-26 | ||
| Anders Jack | Sale | -5,418 | $74 | $400,932 | 2025-11-26 |
| Anders Jack | Derivatives Exercise | 5,418 | 2025-11-26 | ||
| Cislini Jeff | Sale | -13,388 | $70.14 | $939,008 | 2025-11-20 |
| Cislini Jeff | Derivatives Exercise | 13,388 | 2025-11-20 | ||
| GOLDSMITH MARK A | Sale | -20,000 | $70.38 | $1,407,586 | 2025-11-20 |
| GOLDSMITH MARK A | Derivatives Exercise | 20,000 | 2025-11-20 | ||
| GOLDSMITH MARK A | Sale | -20,000 | $65.07 | $1,301,410 | 2025-11-14 |
| GOLDSMITH MARK A | Derivatives Exercise | 20,000 | 2025-11-14 | ||
| Anders Jack | Sale | -10,000 | $64 | $640,000 | 2025-11-13 |
| Anders Jack | Derivatives Exercise | 10,000 | 2025-11-13 | ||
| GOLDSMITH MARK A | Sale | -30,000 | $60.31 | $1,809,306 | 2025-11-12 |
| GOLDSMITH MARK A | Derivatives Exercise | 30,000 | 2025-11-12 | ||
| GOLDSMITH MARK A | Sale | -20,000 | $50.47 | $1,009,402 | 2025-10-20 |
| GOLDSMITH MARK A | Derivatives Exercise | 20,000 | 2025-10-20 | ||
| Cislini Jeff | Sale | -12,000 | $55 | $660,000 | 2025-10-20 |
| Cislini Jeff | Derivatives Exercise | 12,000 | 2025-10-20 | ||
| Kelsey Stephen Michael | Sale | -25,000 | $48.54 | $1,213,540 | 2025-10-15 |
| Kelsey Stephen Michael | Derivatives Exercise | 25,000 | 2025-10-15 | ||
| Cislini Jeff | Sale | -1,799 | $44.26 | $79,624 | 2025-09-26 |
| Cislini Jeff | Sale | -1,869 | $45.82 | $85,647 | 2025-09-18 |
| Anders Jack | Sale | -2,320 | $45.82 | $106,314 | 2025-09-18 |
| Wei Lin | Sale | -2,160 | $45.82 | $98,982 | 2025-09-18 |
| Horn Margaret A | Sale | -4,775 | $45.82 | $218,814 | 2025-09-18 |
| Kelsey Stephen Michael | Sale | -5,367 | $45.82 | $245,942 | 2025-09-18 |
| GOLDSMITH MARK A | Sale | -13,411 | $45.82 | $614,558 | 2025-09-18 |
| Kelsey Stephen Michael | Sale | -125,000 | $43.58 | $5,447,138 | 2025-09-15 |
| Kelsey Stephen Michael | Derivatives Exercise | 125,000 | 2025-09-15 | ||
| Anders Jack | Sale | -10,000 | $40.02 | $400,168 | 2025-09-04 |
| Anders Jack | Derivatives Exercise | 10,000 | 2025-09-04 | ||
| GOLDSMITH MARK A | Derivatives Exercise | 37,000 | 2025-07-02 | ||
| Borellini Flavia | Grant, award...etc | 3,142 | 2025-06-30 | ||
| ANDERSON ELIZABETH M | Grant, award...etc | 3,142 | 2025-06-30 | ||
| Clyburn Frank | Grant, award...etc | 2,806 | 2025-06-30 | ||
| Horning Sandra | Grant, award...etc | 3,142 | 2025-06-30 | ||
| Patel Sushil | Grant, award...etc | 3,142 | 2025-06-30 | ||
| Kim Lorence H. | Grant, award...etc | 3,142 | 2025-06-30 | ||
| Borisy Alexis | Grant, award...etc | 3,142 | 2025-06-30 | ||
| Cislini Jeff | Sale | -1,912 | $39.61 | $75,736 | 2025-06-23 |
| Wei Lin | Sale | -2,173 | $39.83 | $86,551 | 2025-06-18 |
| Kelsey Stephen Michael | Sale | -4,289 | $39.83 | $170,831 | 2025-06-18 |
| Anders Jack | Sale | -2,170 | $39.83 | $86,431 | 2025-06-18 |
| Cislini Jeff | Sale | -1,878 | $39.83 | $74,801 | 2025-06-18 |
| GOLDSMITH MARK A | Sale | -13,496 | $39.83 | $537,546 | 2025-06-18 |
| Horn Margaret A | Sale | -3,510 | $39.83 | $139,803 | 2025-06-18 |
| Cislini Jeff | Sale | -2,041 | $38.71 | $79,008 | 2025-03-24 |
| Horn Margaret A | Sale | -3,058 | $39.04 | $119,385 | 2025-03-19 |
| Kelsey Stephen Michael | Sale | -3,294 | $39.04 | $128,599 | 2025-03-19 |
| Anders Jack | Sale | -1,864 | $39.04 | $72,771 | 2025-03-19 |
| Cislini Jeff | Sale | -1,458 | $39.04 | $56,921 | 2025-03-19 |
| GOLDSMITH MARK A | Sale | -11,738 | $39.04 | $458,255 | 2025-03-19 |
| Wei Lin | Grant, award...etc | -20,800 | 2025-03-04 | ||
| GOLDSMITH MARK A | Grant, award...etc | 97,400 | 2025-03-04 | ||
| Wang Xiaolin | Grant, award...etc | 19,000 | 2025-03-04 | ||
| Anders Jack | Grant, award...etc | 20,400 | 2025-03-04 | ||
| Cislini Jeff | Grant, award...etc | 22,000 | 2025-03-04 | ||
| Horn Margaret A | Grant, award...etc | 28,600 | 2025-03-04 | ||
| Kelsey Stephen Michael | Grant, award...etc | 36,600 | 2025-03-04 | ||
| Cislini Jeff | Sale | -2,406 | $40.5 | $97,443 | 2025-01-22 |
| GOLDSMITH MARK A | Derivatives Exercise | 30,846 | 2024-12-20 | ||
| Anders Jack | Sale | -2,635 | $45.4 | $119,639 | 2024-12-18 |
| Horn Margaret A | Sale | -4,329 | $45.4 | $196,553 | 2024-12-18 |
| GOLDSMITH MARK A | Sale | -11,714 | $45.4 | $531,860 | 2024-12-18 |
| Cislini Jeff | Sale | -1,599 | $45.4 | $72,601 | 2024-12-18 |
| Kelsey Stephen Michael | Sale | -4,663 | $45.4 | $211,718 | 2024-12-18 |
The information provided in this report about RVMD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Revolution Medicines, Inc(NASDAQ:RVMD) 
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gyne...
Website: http://www.revmed.com
Founded: 2014
Full Time Employees: 117
CEO: Mark A. Goldsmith
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends